Evidence map›Paper›PMID 38459103›Full record

ArticleScientific reports2024

Incidence, risk and prognosis of second primary malignancy of patients with gastric adenocarcinoma.

Liyan Jin, Xinyue Su, Wenjing Li, Jie Wu, Hua Zhang

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Receptor status, molecular subtypes, and survival outcomes of breast cancer following gastric cancer compared with single primary breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. Racial/ethnic and geographic differences in second primary cancers in stomach cancer survivors: a comparative study of U.S. and South Korea.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  4. Article
  5. Follow-Up and Strategies After Curative Surgical Resection for Gastric Cancer.The Korean journal of helicobacter and upper gastrointestinal research · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Liyan JinDepartment of Oncology, Wujin Hospital Affiliated with Jiangsu University, Yong Ning North Road No. 2, Changzhou, 213000, Jiangsu, China.
Xinyue SuDepartment of Public Course, Jiangsu College of Nursing, Science Road No. 9, Huai'an, 210023, Jiangsu, China.
Wenjing LiDepartment of Oncology, Wujin Hospital Affiliated with Jiangsu University, Yong Ning North Road No. 2, Changzhou, 213000, Jiangsu, China.
Jie WuDepartment of Oncology, Wujin Hospital Affiliated with Jiangsu University, Yong Ning North Road No. 2, Changzhou, 213000, Jiangsu, China.
Hua ZhangDepartment of Oncology, Wujin Hospital Affiliated with Jiangsu University, Yong Ning North Road No. 2, Changzhou, 213000, Jiangsu, China. zhanghua@wjrmyy.cn.
Xuzhou Medical College · CNJiangsu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the long-term low survival rates of gastric adenocarcinoma (GAC) patients, the occurrence and prognosis of second primary malignancies (SPMs) are often underreported and overlooked as a significant concern.To date, only a few studies have addressed this issue in the context of GAC. These studies, however, are limited by their small patient cohorts and lack of substantial, meaningful findings. Our study aims to fill this gap by investigating the incidence, risk factors, and prognostic significance of SPMs among GAC survivors. Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, we analysed data from patients diagnosed with GAC between 2000 and 2020. The study employs the standardized incidence ratio (SIR) to assess the relative risk of SPMs, competing risk regression to identify risk factors for SPM development after GAC, and Kaplan-Meier and COX regression analyses for survival outcomes. Out of 44,041 GAC patients analyzed, 2,032 (4.3%) developed SPMs, with a median latency period of 36 months. The incidence of SPMs was significantly higher in GAC patients (SIR 1.36, 95% CI 1.32-1.4, EAR 53.57) compared to the general population. Key factors including older age, sex, tumor grade, summary stage, and history of surgical and radiation therapy were related to the higher risk of developing SPMs following GAC. Interestingly, GAC patients without SPMs exhibited poorer overall survival compared to those with SPMs. Age, summary stage, and surgical history were identified as independent prognostic factors for GAC patients with SPMs. This comprehensive analysis underscores the necessity of vigilant monitoring and tailored follow-up for SPMs in GAC survivors, highlighting the study's contribution to enhancing GAC survivors care strategies.

Indexed as

AdenocarcinomaNeoplasms, Second PrimaryStomach NeoplasmsHumansIncidencePrognosisRisk FactorsSEER ProgramGastric cancerSecond primary malignancySEERSurvival analysis

Identifiers

PMID38459103
PMCPMC10923795
OpenAlexW4392602600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.